
Sign up to save your podcasts
Or


Dr. Eric Feigl-Ding is an epidemiologist and health economist and a Senior Fellow at the Federation of American Scientists in Washington DC, and Chief Health Economist for Microclinic International. He was previously a faculty and researcher at Harvard Medical School and Harvard Chan School of Public Health between 2004-2020, and an epidemiologist at the Brigham and Women’s Hospital.
In January 2020, he was recognized in the media as one of the first to alert the public on the pandemic risk of COVID-19. He focuses his efforts on analyzing COVID-19 trends, stop COVID-19 misinformation, advocate for public health, and improve health policy. Dr. Feigl-Ding’s work focuses on the intersection of public health and public policy.
He also currently works on social-network based behavioral interventions for prevention, drug safety, diabetes/obesity prevention, and public health programs in the US and globally. He has further expertise in designing and conducting randomized trials, systematic reviews, public health programs, and improving health policy.
LYRICS:
By Jack Stafford4.5
1313 ratings
Dr. Eric Feigl-Ding is an epidemiologist and health economist and a Senior Fellow at the Federation of American Scientists in Washington DC, and Chief Health Economist for Microclinic International. He was previously a faculty and researcher at Harvard Medical School and Harvard Chan School of Public Health between 2004-2020, and an epidemiologist at the Brigham and Women’s Hospital.
In January 2020, he was recognized in the media as one of the first to alert the public on the pandemic risk of COVID-19. He focuses his efforts on analyzing COVID-19 trends, stop COVID-19 misinformation, advocate for public health, and improve health policy. Dr. Feigl-Ding’s work focuses on the intersection of public health and public policy.
He also currently works on social-network based behavioral interventions for prevention, drug safety, diabetes/obesity prevention, and public health programs in the US and globally. He has further expertise in designing and conducting randomized trials, systematic reviews, public health programs, and improving health policy.
LYRICS:

3,280 Listeners

1,041 Listeners

2,345 Listeners